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hemorrhagic Cystitis Requiring Bladder Irrigation is 
Associated with poor Mortality in hospitalized Stem Cell 
Transplant patients
_______________________________________________
Valary T. Raup 1, Aaron M. Potretzke 1, Brandon J. Manley 1, John A. Brockman 1, Sam B. Bhayani 1
1 Division of Urology, Washington University School of Medicine, Washington, DC, USA
ABSTRACT         ARTICLE INFO______________________________________________________________     ______________________
Purpose: To evaluate the overall prognosis of post-stem cell transplant inpatients who 
required continuous bladder irrigation (CBI) for hematuria.
Materials and Methods: We performed a retrospective analysis of adult stem cell trans-
plant recipients who received CBI for de novo hemorrhagic cystitis as inpatients on the 
bone marrow transplant service at Washington University from 2011-2013. Patients 
who had a history of genitourinary malignancy and/or recent surgical urologic inter-
vention were excluded. Multiple variables were examined for association with death.
Results: Thirty-three patients met our inclusion criteria, with a mean age of 48 years 
(23-65). Common malignancies included acute myelogenous leukemia (17/33, 57%), 
acute lymphocytic leukemia (3/33, 10%), and peripheral T cell lymphoma (3/33, 10%). 
Median time from stem cell transplant to need for CBI was 2.5 months (0 days-6.6 
years). All patients had previously undergone chemotherapy (33/33, 100%) and 14 had 
undergone prior radiation therapy (14/33, 42%). Twenty-eight patients had an infec-
tious disease (28/33, 85%), most commonly BK viremia (19/33, 58%), cytomegalovirus 
viremia (17/33, 51%), and bacterial urinary tract infection (8/33, 24%). Twenty-two 
patients expired during the same admission as CBI treatment (22/33 or 67% of total 
patients, 22/28 or 79% of deaths), with a 30-day mortality of 52% and a 90-day mor-
tality of 73% from the start of CBI.
Conclusions: Hemorrhagic cystitis requiring CBI is a symptom of severe systemic dise-
ase in stem cell transplant patients. The need for CBI administration may be a marker 
for mortality risk from a variety of systemic insults, rather than directly attributable 
to the hematuria.
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Hemorrhagic cystitis is a significant cau-
se of morbidity in immunocompromised patients 
on the Bone Marrow Transplant (BMT) service, 
occurring in up to 30% of hematopoietic stem 
cell transplant recipients (1-3). The most preva-
lent causes of hemorrhage include toxic effects 
of chemotherapy, infection, and radiation cystitis 
(2). Cyclophosphamide and busulfan are the most 
common chemotherapeutic agents causing he-
morrhagic cystitis, while polyoma BK virus, ade-
novirus, and cytomegalovirus are the most com-
mon infectious agents (4, 5). Polyoma BK viremia, 
specifically, has been shown to be correlated with 
increased severity of hemorrhagic cystitis but not 
with increased mortality (6). Other reported predis-
posing factors to the development of hemorrhagic 
cystitis include thrombocytopenia, coagulopathy, 
and possibly graft-versus-host disease (GVHD) (7). 
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Often urologic consultation is obtained on these 
patients when there is a need for continuous bla-
dder irrigation (CBI). The primary goals of this 
study were to characterize the patients requiring 
CBI for hemorrhagic cystitis after hematopoietic 
stem cell transplant and assess all-cause morta-
lity of this cohort.
MATERIALS AND METHODS
A retrospective review was performed of 
33 adult patients who received CBI for hemorrha-
gic cystitis as inpatients on the BMT service at 
Washington University between 2011-2013. Data 
collection began after receiving Institutional Re-
view Board approval. Only patients who had un-
dergone prior hematopoietic stem cell transplant 
were included in the study, and patients who had 
a history of genitourinary malignancy and/or had 
undergone a recent surgical urologic intervention 
were excluded.
Pre-CBI complete blood count values were 
collected < 24 hours prior to the start of CBI tre-
atment. Infectious diseases were identified with 
blood culture, urine culture, or quantitative viral 
polymerase chain reaction analysis, as appropria-
te. CBI treatment was provided through a triple 
lumen urinary catheter. All patients initially re-
ceived intravesical irrigations of saline solution. 
Clinical variables were retrospectively reviewed, 
and outcomes were assessed to see if hemorrhagic 
cystitis was associated with prognosis or systemic 
disease.
Student’s t-test was used to compare 
continuous, normally distributed variables, and 
Welch’s t-test was used to compare continuous, 
non-normally distributed variables. All statistical 




Mean age of the study population was 48 
years (range 23-65), with a median Charleston Co-
morbidity Index (CCI) of 2 (0-6). Thirty patients 
had a hematologic malignancy (30/33, 91%), 2/33 
patients had myelodysplastic syndrome (MDS) 
(6%), and 1/33 patient had aplastic anemia (3%). 
Malignancies included acute myelogenous leu-
kemia (AML) (17/33, 57%), acute lymphoblastic 
leukemia (ALL) (3/33, 10%), peripheral T cell lym-
phoma (3/33, 10%), diffuse large B cell lymphoma 
(2/33, 7%), Hodgkin’s lymphoma (2/33, 7%), mul-
tiple myeloma (1/33, 3%), Mantle cell lymphoma 
(1/33, 3%), and Sézary syndrome (1/33, 3%). De-
tails of the patients’ characteristics and relation to 
mortality can be found in Table-1. As expected, 
malignancy demonstrated a significant associa-
tion with mortality (p=0.015).
All patients had received a prior hemato-
poietic stem cell transplant, with a median time 
from transplant to need for CBI of 2.5 months 
(range: 0 days-6.6 years). All 33 patients also had 
previously undergone chemotherapy, with the 
most prevalent agents including cyclophosphami-
de (25), cytarabine (21), busulfan (13), vincristine 
(11), idarubicin (10), and etoposide (10). Fourteen 
patients had undergone prior radiation therapy 
(14/33, 42%), none of which had treatment direc-
ted to the pelvis. Details of treatment characteris-
tics and relation to mortality can be found in Ta-
ble-2. Radiation or chemotherapy alone were not 
independent risk factors for mortality, but obviou-
sly may be correlated with stem cell transplant, 
therefore they cannot be exclusively separated. No 
specific prior oncologic treatment was uniquely 
significant over other treatments.
Twenty-eight patients were found to have 
an infectious disease (28/33, 85%), most com-
monly BK viremia (19/33, 58%), cytomegalovirus 
viremia (17/33, 51%), and bacterial urinary tract 
infection (UTI) (8/33, 24%). Twenty-three patients 
had pre-existing GVHD (23/33, 70%), frequently 
of the gastrointestinal (GI) tract (16/33, 48%), skin 
(6/33, 18%), or liver (5/33, 15%). Median pre-CBI 
complete blood count values showed patients to 
be leukopenic at 1.9 x 103/μL, anemic at 9.4g/dL 
and thrombocytopenic at 18 x 103/μL. Details of 
infectious diseases and GVHD and their associa-
tion with mortality can be found in Table-3.
Two patients eventually required instilla-
tion of 1% alum solution to control hemorrhage 
(2/33, 6%), and 6 patients required cystoscopy 
with clot evacuation after initiation of CBI (6/33, 
18%) for removal of recurrent clots. Neither need 
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at 90 days (n=24)
P-value
Average Age (in years) 48 49
Median CCI 2 2 1.000
Malignancy 30 24 0.015
AML 17 14 0.259
MM 1 1 1.000
ALL 3 3 0.545
PTCL 3 2 1.000
DLBCL 2 1 0.477
HL 2 2 1.000
ML 1 1 1.000
SS 1 0 0.273
MDS 2 0 0.068
Aplastic Anemia 1 0 0.273
CCI = Charleston Comorbidity Index; AML = acute myelogenous leukemia; MM = multiple myeloma; ALL = acute lymphoblastic leukemia; PTCL = peripheral T cell 
lymphoma; DLBCL = diffuse large B cell lymphoma; HL = Hodgkin's lymphoma; ML = Mantle cell lymphoma; SS = Sezary syndrome.
Table 2 - Prior oncological treatments as risk factors for 90-day mortality.
Treatment Total Deceased (at 90 days) P-value
Radiation 14 9 0.442
Chemotherapy
Cyclophosphamide 25 17 0.394
Cytarabine 21 17 0.230
Idarubicin 10 8 0.686
Etoposide 10 7 1.000
Busulfan 13 10 1.000
Vincristine 11 9 0.681 
for instillation of alum solution nor need for cys-
toscopy with clot evacuation was shown to be as-
sociated with changes in 30- or 90-day mortality 
(30-day p=0.21, 0.40, 90-day p=0.47, 1.00).
Descriptors of Mortality Analysis
Twenty-eight patients were deceased at the 
time of last follow-up (28/33, 85%). Average age 
at death was 49 years, with median time to death 
from initiation of CBI of 22 days (0-804 days). 
Of these patients, twenty-two patients died during 
the same admission of CBI treatment (22/28 or 
79% of deaths, 22/33 or 67% of total patients). 
Thirty-day mortality was found to be 52% (17/33), 
and 90-day mortality was 73% (24/33).
We assessed factors possibly related to 
mortality in our cohort. Nearly all of the patients 
who were deceased at the time of last follow-up 
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died from cancer related causes and subsequent 
multi-organ failure (27/28, 96%). Neither mean 
age nor median CCI at time of admission were 
shown to be associated with increased 30- or 90-
day mortality. Treatment with chemotherapy in 
general or any specific agent was not shown to 
be associated with mortality. Similarly, radiation 
was not associated with increased mortality. In-
fectious diseases, pre-existing GVHD, neutrope-
nia, anemia, and thrombocytopenia were also not 
shown to be specifically associated with increased 
mortality.
DISCUSSION
Our findings demonstrate that hemorrhagic 
cystitis requiring CBI in patients having undergo-
ne stem cell transplant is associated with a high 
30-day and 90-day mortality rate. A previous stu-
dy from our institution showed a 90-day morta-
lity rate of 12% after stem cell transplant (8). The 
present study, however, demonstrates a markedly 
higher mortality rate in this cohort with hemor-
rhagic cystitis requiring CBI, the 90-day mortality 
rate was 73%. It is important to note that this is 
an association, but not an assertion of cause. In 
our best assessment, this cohort’s development of 
hemorrhagic cystitis seems to be part of an ove-
rall picture of severe medical illness, rather than 
a specific cause of mortality. Hence, hemorrhagic 
cystitis requiring CBI is likely a urological marker 
of severe systemic insults within this population. 
Hematuria was not the cause of death in these pa-
tients, but rather was just another marker for se-
vere systemic disease.
Hemorrhagic cystitis is a significant cause 
of morbidity in stem cell transplant patients, with 
most common etiologies including toxic effects 
of chemotherapy, infection, and radiation cystitis. 
However, these patients regularly have many pre-
disposing factors, thereby causality is difficult to 
assign. The statistical challenge of demonstrating 
significant relationships is compounded by the re-
latively small cohort size and overall high morta-
lity risk across the entire cohort, thereby making 
it unlikely that any patient factor would be more 
significant than others (Tables 1-3). For example, 
cyclophosphamide has been shown to be the most 
common chemotherapeutic agent causing hemor-
rhagic cystitis in the literature (4, 9, 10). Most of 
the patients (88%) who received chemotherapy 
also had other risk factors for development of 
hematuria such as viruria, bacteria, or radiation, 
thus cause cannot be clearly identified. This fur-
ther supports the idea that hemorrhagic cystitis is 
a symptom of severe systemic disease rather than 
a causative mortality factor.
In our study, more than half (67%) of the 
patients died during the same admission in which 
occurred CBI. The overall 30-day mortality was 
Table 3 - Additional possible risk factors of mortality.
Risk Factor Total Deceased (at 90 days) P-value
Infectious Disease 28 22 0.111
BK Virus 19 14 1.000
CMV 17 12 1.000
VRE UTI 6 4 1.000
Klebsiella UTI 2 1 0.477
Enterobacter UTI 1 1 1.000
GVHD 23 16 0.547
Gastrointestinal 16 13 0.111
Skin 6 3 0.653
Liver 5 5 0.143
CMV = cytomegalovirus; VRE = vancomycin-resistant enterococci; UTI = urinary tract infection; GVHD = graft-versus-host disease
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52%, and 90-day mortality was 73%. Padilla-Fer-
nandez et al. found a slightly lower overall mor-
tality rate of 51.14% in a population of 52 post-
-hematopoietic stem cell transplant patients with 
hemorrhagic cystitis, although the authors did not 
specifically examine patients with severe enou-
gh hemorrhagic cystitis to merit CBI (11). In their 
study, hemorrhagic cystitis was also not found to 
be the cause of death in any patient. Neverthe-
less, this consistently high mortality risk should 
concern urologists in planning overall treatment 
and care of these patients. Given that no patients 
died directly from hemorrhage, and additional in-
terventions were not found to impact mortality, 
perhaps treatment plans should be made with pa-
ramount consideration of patient comfort. Unless 
a patient is actively exsanguinating due to the se-
verity of their hematuria, care may be limited to 
CBI, and clinicians should use this high mortality 
rate to more accurately advise families on prog-
nosis.
Under more typical circumstances, treat-
ments of hemorrhagic cystitis require the patient 
to be free of bladder clots, which can be achieved 
with aggressive manual irrigation or cystoscopy 
with clot evacuation and fulguration. Once the 
bladder is clear, continuous bladder irrigation is 
initiated to prevent further clot development and 
retention. Mild hemorrhages can be treated with 
sodium chloride instillation, while more severe 
cases require instillation of aminocaproic acid, 
alum, silver nitrate, phenol, or formaldehyde (12). 
In refractory cases, hyperbaric oxygen therapy or 
embolization of the internal iliac arteries can be 
employed (13, 14). Surgical options such as uri-
nary diversion or cystectomy are an option if all 
other therapies are unsuccessful (15). Fibrin glue 
therapy is a novel technique that has been recen-
tly described by Tirindelli et al., who showed that 
this treatment increased the 6-month probability of 
survival when used in post-allogenic hematopoietic 
stem cell transplant patients (16).
Our study has several limitations. This 
project is both retrospective and hypothesis ge-
nerating, thus larger-scale prospective studies are 
necessary to investigate possible associations be-
tween hemorrhagic cystitis, predisposing factors, 
and increased mortality. Nevertheless, a randomi-
zed or prospective study may not be practical or 
possible in this population. In addition, a matched 
cohort study comparing the mortality rates be-
tween similar patients with and without hemor-
rhagic cystitis would be necessary to truly elu-
cidate a statistically significant risk of mortality 
in post-stem cell transplant patients with hemor-
rhagic cystitis.
CONCLUSIONS
Hemorrhagic cystitis requiring CBI is an 
indicator of severe systemic disease in patients 
who underwent previous stem cell transplantation 
via either peripheral blood or BMT. The need for 
CBI administration may portend an increased risk 
of mortality for hospitalized stem cell transplant 
patients. The urologist has a unique perspective 
when receiving a consultation for CBI in a BMT 
patient. Counseling of the patient, family, and 
other providers is paramount. Further studies and 
improved strategies for management of these pa-
tients are needed.
ABBREVIATIONS
CBI = continuous bladder irrigation
BMT = bone marrow transplant
AML = acute myelogenous leukemia
ALL = acute lymphoblastic leukemia
UTI = urinary tract infection
GVHD = graft-versus-host disease
MDS = myelodysplastic syndrome
CCI = Charleston Comorbidity Index
MM = multiple myeloma
PTCL = peripheral T cell lymphoma
DLBCL = diffuse large B cell lymphoma
HL = Hodgkin’s lymphoma
ML = Mantle cell lymphoma
SS = Sézary syndrome
CMV = cytomegalovirus
GI = gastrointestinal
VRE = vancomycin-resistant enterococcus
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